TEVA PHARMACEUTICAL INDUSTRIES LTD·4

Mar 6, 7:18 AM ET

McClellan Michael James 4

4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 6, 2019

Insider Transaction Report

Form 4
Period: 2019-03-04
McClellan Michael James
EVP, Chief Financial Officer
Transactions
  • Award

    Restricted Share Units

    2019-03-04+50,74650,746 total
    Ordinary Shares (50,746 underlying)
Footnotes (3)
  • [F1]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  • [F2]Restricted share units were granted on March 4, 2019, with 16,915 vesting on each of March 4, 2021 and March 4, 2022 and 16,916 vesting on March 4, 2023.
  • [F3]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION